B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S

被引：1

作者：

Jacob-Dolan, Catherine ^{[1
,2
,3
]}

Lifton, Michelle ^{[1
]}

Powers, Olivia C. ^{[1
]}

Miller, Jessica ^{[1
]}

Hachmann, Nicole P. ^{[1
]}

Vu, Mya ^{[2
]}

Surve, Nehalee ^{[1
]}

Mazurek, Camille R. ^{[1
]}

Fisher, Jana L. ^{[1
]}

Rodrigues, Stefanie ^{[1
]}

Patio, Robert C. ^{[1
]}

Anand, Trisha ^{[1
]}

Le Gars, Mathieu ^{[4
]}

Sadoff, Jerald ^{[4
]}

Schmidt, Aaron G. ^{[2
,3
]}

Barouch, Dan H. ^{[1
,2
,3
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA

[2] MIT & Harvard, Ragon Inst Mass Gen, Cambridge, MA 02139 USA

[3] Harvard Med Sch, Dept Microbiol, Boston, MA 02115 USA

[4] Janssen Vaccines & Prevent BV, Leiden, Netherlands

来源：

ISCIENCE | 2024年 / 27卷 / 05期

关键词：

monoclonal antibodies; long term affinity; AFFINITY MATURATION; NEUTRALIZING ANTIBODIES; TRANSMISSION; DYNAMICS; EFFICACY; POTENCY; ESCAPE; TRIAL;

D O I：

10.1016/j.isci.2024.109716

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The viral vector -based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time, even in the absence of boosting or infection. Here, we studied humoral responses following Ad26.COV2.S vaccination in individuals enrolled in the initial Phase 1/2a trial of Ad26.COV2.S in 2020. Through 8 months post vaccination, serum NAb responses increased to variants, including B.1.351 (Beta) and B.1.617.2 (Delta), without additional boosting or infection. The level of somatic hypermutation, measured by nucleotide changes in the VDJ region of the heavy and light antibody chains, increased in Spike -specific B cells. Highly mutated mAbs from these sequences neutralized more SARS-CoV-2 variants than less mutated comparators. These findings suggest that the increase in NAb breadth over time following Ad26.COV2.S vaccination is mediated by affinity maturation.

引用

页数：13

共 50 条

[21] Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol
Sablerolles, Roos S. G.
Goorhuis, Abraham
GeurtsvanKessel, Corine H.
de Vries, Rory D.
Huckriede, Anke L. W.
Koopmans, Marion P. G.
Lafeber, Melvin
Postma, Douwe F.
van Baarle, Debbie
Visser, Leo G.
Dalm, Virgil A. S. H.
Kootstra, Neeltje A.
Rietdijk, Wim J. R.
van der Kuy, P. Hugo M.
FRONTIERS IN IMMUNOLOGY, 2021, 12
[22] Evaluation of Anti-PF4 Positivity and Platelet Activation after COVID-19 Vaccination with Ad26.COV2.S in Brazil
Bokel, Joanna
Mendes-de-Almeida, Daniela P.
Martins-Goncalves, Remy
Grinsztejn, Eduarda
Hoagland, Brenda
Wagner, Sandra
Geraldo, Kim Mattos
Coutinho, Sandro Nazer
Georg, Ingebourg
Oliveira de Mello, Maria Helena
Souza, Flavia dos Santos
Vizzoni, Alexandre G.
Veloso, Valdilea
Bozza, Patricia T.
Grinsztejn, Beatriz
BLOOD, 2022, 140 : 8505 - 8506
[23] Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
Sadoff, J.
Le Gars, M.
Shukarev, G.
Heerwegh, D.
Truyers, C.
de Groot, A. M.
Stoop, J.
Tete, S.
Van Damme, W.
Leroux-Roels, I
Berghmans, P-J
Kimmel, M.
Van Damme, P.
de Hoon, J.
Smith, W.
Stephenson, K. E.
De Rosa, S. C.
Cohen, K. W.
McElrath, M. J.
Cormier, E.
Scheper, G.
Barouch, D. H.
Hendriks, J.
Struyf, F.
Douoguih, M.
Van Hoof, J.
Schuitemaker, H.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (19): : 1824 - 1835
[24] Article Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
Geers, Daryl
Sablerolles, Ross S. G.
Baarle, Debbie van
Kootstra, Neeltje A.
Rietdijk, Wim J. R.
Schmitz, Katharina S.
Gommers, Lennert
Bogers, Susanne
Nieuwkoop, Nella J.
van Dijk, Laura L. A.
van Haren, Eva
Lafeber, Melvin
Dalm, Virgil A. S. H.
Goorhuis, Abraham
Postma, Douwe F.
Visser, Leo G.
Huckriede, Anke L. W.
Sette, Alessandro
Grifoni, Alba
de Swart, Rik L.
Koopmans, Marion P. G.
van der Kuy, P. Hugo M.
GeurtsvanKessel, Corine H.
de Vries, Rory D.
SWITCH Res Grp
ISCIENCE, 2023, 26 (01)
[25] VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis
Kennedy, Vanessa E.
Wong, Chelsea C.
Hong, Jessica M.
Peng, Theodore
Brondfield, Sam
Reilly, Linda M.
Cornett, Patricia
Leavitt, Andrew D.
BLOOD ADVANCES, 2021, 5 (22) : 4662 - 4665
[26] Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
Shant H. Mahrokhian
Lisa H. Tostanoski
Catherine Jacob-Dolan
Roland C. Zahn
Frank Wegmann
Katherine McMahan
Jingyou Yu
Makda S. Gebre
Esther A. Bondzie
Huahua Wan
Olivia Powers
Tianyi Ye
Julia Barrett
Hanneke Schuitemaker
Dan H. Barouch
npj Vaccines, 7
[27] Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
Mahrokhian, Shant H.
Tostanoski, Lisa H.
Jacob-Dolan, Catherine
Zahn, Roland C.
Wegmann, Frank
McMahan, Katherine
Yu, Jingyou
Gebre, Makda S.
Bondzie, Esther A.
Wan, Huahua
Powers, Olivia
Ye, Tianyi
Barrett, Julia
Schuitemaker, Hanneke
Barouch, Dan H.
NPJ VACCINES, 2022, 7 (01)
[28] Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination
Bova, Carlo
Vigna, Ernesto
Gentile, Massimo
IDCASES, 2022, 27
[29] A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination
Morehouse, Zachary P.
Paulus, Amanda
Jasti, Sri A.
Bing, Xue
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
[30] Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester
Citu, Ioana Mihaela
Citu, Cosmin
Gorun, Florin
Sas, Ioan
Tomescu, Larisa
Neamtu, Radu
Motoc, Andrei
Gorun, Oana Maria
Burlea, Bogdan
Bratosin, Felix
Malita, Daniel
VIRUSES-BASEL, 2022, 14 (02):

← 1 2 3 4 5 →